Eli Lilly and Company (LLY) support and resistance · P/E 39, rev $65.18B
Eli Lilly and Company (LLY) is a drug manufacturers - general company listed on NYSE. It is led by David Ricks.
This page maps Eli Lilly and Company (LLY) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported LLY revenue for 2025-12-31 was $65.18B. Net income was $20.64B. Revenue was up 44.7% from 2024-12-31 to 2025-12-31. LLY currently screens at market cap $991.62B and trailing P/E 39.5.
LLY currently screens at market cap $991.62B and trailing P/E 39.5. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new LLY 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the LLY quote page for the session range and the stock page for the full model.
Not investment advice.